Clinical Endoscopy (Jul 2024)

Clinical meaning of sarcopenia in patients undergoing endoscopic treatment

  • Hiroyuki Hisada,
  • Yosuke Tsuji,
  • Hikaru Kuribara,
  • Ryohei Miyata,
  • Kaori Oshio,
  • Satoru Mizutani,
  • Hideki Nakagawa,
  • Rina Cho,
  • Nobuyuki Sakuma,
  • Yuko Miura,
  • Hiroya Mizutani,
  • Daisuke Ohki,
  • Seiichi Yakabi,
  • Yu Takahashi,
  • Yoshiki Sakaguchi,
  • Naomi Kakushima,
  • Nobutake Yamamichi,
  • Mitsuhiro Fujishiro

DOI
https://doi.org/10.5946/ce.2023.193
Journal volume & issue
Vol. 57, no. 4
pp. 446 – 453

Abstract

Read online

With increasing global life expectancy, the significance of geriatric assessment parameters has increased. Sarcopenia is a crucial assessment parameter and is defined as the age-related loss of muscle mass and strength. Sarcopenia is widely acknowledged as a risk factor for postoperative complications in diverse advanced malignancies and has a detrimental effect on the long-term prognosis. While most studies have primarily concentrated on the correlation between sarcopenia and advanced cancer, more recent investigations have focused on the relationship between sarcopenia and early-stage cancer. Endoscopic submucosal dissection (ESD), which is less invasive than surgical intervention, is extensively employed in the management of early-stage cancer, although it is associated with complications such as bleeding and perforation. In recent years, several reports have revealed the adverse consequences of sarcopenia in patients with early-stage cancer undergoing ESD. This literature review briefly summarizes the recent studies on the association between sarcopenia and ESD.

Keywords